[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578496":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":53,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":21,"enrollmentInfo":65,"targetDuration":21,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":21,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hypofractionated Radiation Therapy","EXPERIMENTAL","This group is receiving hypofractionated radiation therapy (shorter course of radiation therapy)",[13,14],"Radiation: Radiation Therapy","Radiation: Hypofractionationed Radiation Therapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Radiation Therapy","In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Hypofractionationed Radiation Therapy","This group is receiving hypofractionated radiation therapy (shorter course of RT)",[9],[27],{"name":28,"affiliation":29,"role":30},"Miranda Lam","Dana-Farber\u002FBrigham and Women's Cancer Center","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","617-732-7948","miranda_lam@dfci.harvard.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Brigham and Women's Hospital \u002F Dana Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02446","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-71.05977,42.35843,{"lat":49,"lon":48},[52],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},{"type":30,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Miranda Lam, MD","Radiation Oncologist","100578496","phase-1-short-course-radiation-treatment-for-patients-with-primary-or-locally-recurrent-retroperitoneal-sarcoma-prior-to-surgery-100578496",false,"NCT06812052","Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery","Prospective Phase I Trial of Hypofractionated Radiation Therapy in Retroperitoneal Sarcoma","Inclusion Criteria:\n\n* Participants must have a histologically confirmed STS of the retroperitoneal space or infra-peritoneal spaces of pelvis\n* Participant must have radiologically measurable disease (RECIST 1.1), as confirmed by abdomino-pelvic CT or MRI\n* Participant must have primary, locally recurrent, or metastatic disease requiring treatment of the retroperitoneal mass\n* Tumor must be suitable for radiotherapy and surgery based on pre-treatment CT scan\u002FMRI in multidisciplinary discussion with surgeon and radiation oncologist (anticipated macroscopically complete resection, R0\u002FR1 resection)\n* Age: 18 years or older\n* ECOG performance status ≤2\n* Absence of history of bowel obstruction, mesenteric ischemia, or severe chronic inflammatory bowel disease.\n* Normal renal function (calculated creatinine clearance ≥50 mL\u002Fmin)\n* Normal bone marrow and hepatic function (white blood cell count ≥2·5 × 10⁹ cells per L, platelet count ≥80 × 10⁹ cells per L, and total bilirubin \\\u003C2 times upper limit of normal)\n* Women of child-bearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment\n* Patients capable of childbearing\u002Freproductive potential should use adequate contraception\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Sarcoma originating from bone structure, abdominal or gynecological viscera\n* Any of the following histological subtypes: gastrointestinal stromal tumor, rhabdomyosarcoma, primitive neuroectodermal tumor or other small round blue cell sarcoma, osteosarcoma, chondrosarcoma, aggressive fibromatosis, or sarcomatoid or metastatic carcinoma\n* Prior RT to the RPS\n* Prior abdominal or pelvic irradiation for other prior malignancy or other disease\n* Prior different invasive malignancy may be eligible per the discretion of the treating investigator and review by the Principal Investigator (PI)\n* Prior chemotherapy or immunotherapy within 6 weeks of start of RT\n* Pregnant women are excluded from this study because RT has the potential for teratogenic or abortifacient effects.\n* HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for increased sensitivity to RT","ALL","18 Years",{"count":66,"type":67},6,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)",[73],"Retroperitoneal Sarcoma","2025-10-11",{"date":76,"type":77},"2025-10-14","ACTUAL",{"date":79,"type":77},"2025-05-29",{"date":81,"type":67},"2026-11",{"name":5,"class":6},1]